Standardized pressure provocation as an objective clinical marker of omalizumab response in delayed pressure urticaria: an open-label, real-life, prospective cohort
BackgroundDelayed pressure urticaria (DPU) is a disabling chronic inducible urticaria characterized by delayed painful swelling after sustained pressure. Evidence-based therapeutic options remain limited, and omalizumab is frequently used off-label in …